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Mutations in the parkin gene are a predominant cause of familial parkinsonism. Although initially described as a recessive disorder,
emerging evidence suggest that single parkin mutations alone may confer increased susceptibility to Parkinson’s disease. To better
understand the effects of parkin mutations in vivo, we generated transgenic Drosophila overexpressing two human parkin missense
mutants, R275W and G328E. Transgenic flies that overexpress R275W, but not wild-type or G328E, human parkin display an age-
dependent degeneration of specific dopaminergic neuronal clusters and concomitant locomotor deficits that accelerate with age or in
response to rotenone treatment. Furthermore, R275W mutant flies also exhibit prominent mitochondrial abnormalities in their flight
muscles. Interestingly, these defects caused by the expression of humanR275Wparkin are highly similar to those triggered by the loss of
endogenous parkin in parkin null flies. Together, our results provide the first in vivo evidence demonstrating that parkin R275Wmutant
expressionmediates pathogenic outcomes and suggest the interesting possibility that select parkinmutationsmay directly exert neuro-
toxicity in vivo.
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Introduction
Parkinson’s disease (PD) is themost commonneurodegenerative
movement disorder characterized pathologically by the rather
selective loss ofmidbrain dopaminergic neurons in the substantia
nigra pars compacta (Savitt et al., 2006). Most cases of PD occur
in a sporadic manner with unknown etiology. However, a subset
of PD cases is inheritable and attributable tomutations in specific
genes. These familial PD-linked genes include -synuclein, par-
kin, DJ-1, PINK1 (PTEN induced putative kinase 1), and LRRK2
(leucine-rich repeat kinase 2) (Moore et al., 2005; Savitt et al.,
2006).
Mutations in the parkin gene are currently recognized as a
predominant cause of hereditary parkinsonism, accounting for as
much as 50% of familial early-onset PD cases and 2–6% of
late-onset PD cases (Lucking et al., 2000; Klein et al., 2003; Ol-
iveira et al., 2003). These parkin mutations include exonic dele-
tion, duplication, and triplication as well as several missense/
nonsense substitutions. Although initially described as a recessive
disorder, emerging evidence suggest that heterozygous parkin
mutations may confer increased susceptibility to PD (Hilker et
al., 2001, 2002; Oliveira et al., 2003; Khan et al., 2005; L. N. Clark
et al., 2006; Sun et al., 2006). Although parkin haploinsufficiency
may explain for the increased risk for PD associated with single
parkin mutations, the possibility that some parkin heterozygous
mutations may be pathogenic cannot be excluded. Moreover,
certain missense mutations seem to be inherited in an autosomal
dominant manner (Oliveira et al., 2003). Two parkin mutations
that frequently occur in heterozygous state are R275W and
G328E (supplemental Table S1, available at www.jneurosci.org as
supplemental material). We recently demonstrated that these
parkin mutants exhibit different properties from the wild-type
protein when expressed in cells (Sriram et al., 2005; Wang et al.,
2005a). However, their respective effect in vivo remains to be
established.
Recently, the Drosophila has emerged as a good system to
model parkin dysfunction. Although parkin-deficientmice fail to
show robust signs of parkinsonism (Perez and Palmiter, 2005),
Drosophila parkin null mutants exhibit dopaminergic neurode-
generation in the adult brains and concomitant locomotion de-
fects (Cha et al., 2005; Whitworth et al., 2005), a phenotype that
faithfully mirrors the human condition. Furthermore, important
relationship between pathways regulated by parkin and PINK1
has also been established recently through Drosophila studies
(I. E. Clark et al., 2006; Park et al., 2006; Yang et al., 2006).
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To better understand the effects of parkin mutations in vivo,
we generated transgenic Drosophila overexpressing the human
parkinmissensemutants R275W andG328E.We found that flies
overexpressing R275W (but not wild-type or G328E) parkin dis-
play an age-dependent degeneration of specific dopaminergic
neuronal clusters and exhibit accelerated impairment in climbing
ability with age or in response to rotenone treatment when com-
pared with control flies. Furthermore, R275W mutant flies also
exhibit prominent mitochondrial abnormalities. Interestingly,
these effects mediated by parkin R275W mutant are similar to
those triggered by the loss of endogenous parkin in parkin null
flies. Together, our results demonstrate that the expression of
human R275W in Drosophila promotes dopaminergic neurode-
generation andmitochondrial dysfunction and suggest the inter-
esting possibility that select parkin mutations may directly exert
neurotoxicity in vivo.
Materials andMethods
Fly stocks. The parkin null mutant flies ( park1) were kind gifts from
J. Chung and K. S. Cho (Korea Advanced Institute of Science and Tech-
nology, Daejeon, Korea) (Cha et al., 2005). The maternal driver mata-
Gal4 VP16 V32was a kind gift from D. St. Johnston (University of Cam-
bridge, Cambridge, UK). Fly lines for elav-Gal4,Ddc-Gal4, and 24B-Gal4
were obtained from the Bloomington Stock Center (Bloomington, IN).
Wild-type and mutant human parkin (R275W or G328E) cDNAs were
introduced into the galactosidase-4 (GAL4)-responsive pUAST expres-
sion vector. Sequencing of cloned products was performed before they
were microinjected into the embryos. At least two transgenic lines ex-
pressing the respective transgenes above were used in our study.
Immunohistochemistry, muscle histology, and transmission electron mi-
croscopy analysis. Immunohistochemical analysis of whole-mount adult
fly brains were prepared according to published protocols and stained
with rabbit anti-tyrosine hydroxylase (TH) (1:200; Pel-Freez Biologicals,
Milwaukee, WI), rat anti-elav (embryonic lethal, abnormal vision, Dro-
sophila) (1:10; Developmental Studies Hybridoma Bank, University of
Iowa, Iowa City, IA), rat anti-serotonin (1:50; Millipore, Billerica, MA),
or mouse anti-human parkin Prk8 (1:1000; Signet Laboratories, Ded-
ham, MA) as primary antibodies. We analyzed dopaminergic and sero-
tonergic neurons quantitatively in different clusters according to the
method described by Whitworth et al. (2005). The number of dopami-
nergic neurons in the protocerebral anterior medial (PAM) cluster was
not counted, because they are densely populated and less amenable to
confocal microscopy-based quantitation. For transmission electron mi-
croscopy (TEM), muscle tissues were prepared by dissecting thoraces
from 20-d-old adults. These sections were then fixed overnight in 2.5%
glutaraldehyde in 0.1 M phosphate buffer, pH 7.2, before being postfixed
in 1% OsO4 for 1 h. Subsequently, they were dehydrated in an ethanol
series and embedded in Spurr’s resin. Ultrathin sections were stained
with uranyl acetate and lead citrate and observed under a JEM-1230
electron microscope (Jeol, Peabody, MA).
Climbing assays and rotenone treatment. Climbing assays were per-
formed according to the method described by Coulom and Birman
(2004). Three groups of 20 female adult flies that express the transgenes
under the direction of theDdc-GAL4 driverwere anesthetized and placed
in a vertical plastic column (25 cm length, 1.5 cm diameter). Age-
matched wild-type and parkin null flies were used as controls. After a 1 h
recovery period from CO2 exposure, flies were gently tapped to the bot-
tomof the column. The number of flies that reached the top of column at
1min was then counted. Three trials were performed in each experiment
at 15min intervals. The scores represent themean percentage of flies that
reached the top against the total number tested. Results are presented as
mean SEM of the scores obtained in three independent experiments.
In rotenone-treated flies, flies were fed with cornmeal–agar medium
containing 50 M rotenone (Sigma, St. Louis, MO) immediately at after
eclosion and during the entire experimental period.
Statistical analysis. Statistical significance for all the quantitative data
obtained was analyzed using Student’s t test (*p  0.05; **p  0.01)
unless otherwise stated.
Results
Parkin R275Wmutant expression inDrosophila promotes a
similar pattern of dopaminergic neurodegeneration to that
observed in parkin null flies
Because the expression of toxic human proteins inDrosophila has
allowed the accuratemodeling of several human diseases, includ-
ing PD (Muqit and Feany, 2002), we believe that any pathogenic
effects exerted by parkin mutants will manifest within specific
dopaminergic neuronal clusters in transgenic flies producing
them. To examine the effects of parkin R275W and G328E ex-
pression in vivo, we overexpressed these missense mutants in
Drosophilaunder the regulation of theGAL4/upstream activating
sequence (UAS) system. As a control, we also generatedDrosoph-
ila producing wild-type human parkin.
Driven by an elav-GAL4 driver, a pan-neuronal driver, ex-
pression of human wild-type parkin or mutant R275W and
G328E parkin in adult transgenic Drosophila brains expectedly
does not compromise the overall anatomical integrity of the brain
(Fig. 1A). Interestingly, anti-human parkin immunoblotting of
lysates prepared from the brains of these flies (Fig. 1B) reveals an
expression pattern of the various transgenic parkin species that is
similar to their respective expression profile seen in our previous
cell culture studies (Wang et al., 2005a). Whereas “soluble” nor-
mal human parkin shows abundant anti-parkin staining in the
detergent-soluble (S) fraction, the “insoluble” parkin mutants
R275W and G328E show dramatically weaker staining (Fig. 1B).
However, we did not observe the expected relocalization of the
R275WandG328Eparkinmutants to the detergent-insoluble (P)
fraction of the fly brain lysate (Fig. 1B), suggesting that insoluble
parkin species are either actively degraded in vivo or that adult
Drosophila neurons cannot tolerate high expression levels of
these mutants. Supporting this, we observe more comparable
level of expression among the three parkin species when they are
expressed in Drosophila embryos under the control of a ubiqui-
tous driver,mata-Gal4 VP16 V32 (data not shown).
Because the loss of parkin function in Drosophila has been
shown recently to result in progressive degeneration of dopami-
nergic neurons in the protocerebral posterior lateral (PPL) 1 clus-
ter in the adult brain (Whitworth et al., 2005), we wondered
whether the R275W or G328E parkinmutant flies could produce
this feature. To facilitate our study, we used a driver line contain-
ing the promoter for the L-3,4-dihydroxyphenylalanine carboxy-
lase gene (Ddc-GAL4), a promoter specific to TH-positive dopa-
minergic neurons, that allows the dopaminergic neuronal-
specific expression of the transgenes in the adult fly brain.
Consistent with previous report (Whitworth et al., 2005), we
observed an obvious loss of dopaminergic neurons in the PPL1
cluster of parkin null flies compared with age-matched control
flies (Fig. 2A). Strikingly, overexpression of the R275W parkin
mutant in flies produces a similar neurodegeneration pattern as
parkin null flies, whereas the population of PPL1 neurons re-
mains intact in flies expressing wild-type parkin or the G328E
mutant (Fig. 2A). Quantitative analysis of different dopaminer-
gic neuronal clusters in the brains of the various transgenic flies at
different time points reveals a selective, age-dependent, progres-
sive loss of dopaminergic neurons in flies expressing the parkin
R275Wmutant (Fig. 2B). At 2 d after eclosion, the R275W trans-
genic flies lost 20% of its dopaminergic neurons in the PPL1
cluster (relative to age-matched controls) but not in other dopa-
minergic neuronal clusters, including PAL, PPL2, protocerebral
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posteriormedial 1/2 (PPM1/2), and PPM3 (Fig. 2B). At 20 d after
eclosion, the relative percentage neuronal loss in the PPL1 cluster
in R275W flies increased remarkably to 50% (Fig. 2B). Notably,
this rate of PPL1 dopaminergic neurodegeneration in R275W
flies is similar to that exhibited by the parkin null flies (Fig. 2B).
Conversely, no marked degeneration of the PPL1 neurons is ob-
served with transgenic flies overexpressing normal parkin or the
G328E mutant at the time points examined relative to age-
matched controls (Fig. 2B). Besides the PPL1 cluster, the R275W
mutant flies also show a significant reduction of TH-positive
neurons in the PAMcluster comparedwith control flies (Fig. 2C).
This defect is again very similar to that seen in parkin null flies
(Fig. 2C) but is not observed in flies expressing wild-type or
G328E human parkin (Fig. 2C). Dopaminergic neurons in PAL,
PPL2, PPM1/2, and PPM3 clusters remain essentially unaffected
at 20 d after eclosion in all the transgenic flies examined (Fig. 2B).
To complement our above findings, we also examined the
PPL1 cluster in brain sections of elav-GAL4-drivenwild-type and
R275W parkin-expressing flies. We found that flies expressing
R275W parkin in a pan-neuronal manner similarly exhibit
marked PPL1 neuronal loss compared with their corresponding
wild-type parkin counterparts (Fig. 3A). This pattern of dopami-
nergic neurodegeneration is rather selective, because we did not
observe any obvious loss of serotonergic neurons in these flies
(Fig. 3B). Quantitatively, the total number of serotonergic neu-
rons in elav-GAL4-driven wild-type and R275W parkin-
expressing flies remains comparable at 20 d after eclosion (data
not shown). Together, our results demonstrate that overexpres-
sion of the R275W parkin mutant in Drosophila promotes the
degeneration of select dopaminergic neuronal clusters in a simi-
lar manner to that resulting from the loss of endogenous parkin.
Parkin R275Wmutant flies exhibit locomotor deficits
To examinewhether R275Wparkin-induced degeneration of do-
paminergic neurons in transgenic flies influences their geotactic
climbing behavior, we tested the climbing ability of the various
transgenic flies at 5 d intervals for a period of 30 d (Fig. 4). At 10 d
after eclosion, we begin to observe significant and comparable
impairment in the climbing ability of parkin null flies and those
overexpressing the R275W mutant relative to age-matched con-
trols (Fig. 4). The climbing defects in these flies progressively
becomeworse in an age-dependentmanner (Fig. 4). At the end of
the experiment, both the R275Wand parkin null flies couldman-
age only 10% success rate compared with control flies. Con-
versely, flies that overexpress wild-type or G328E parkin did not
exhibit significantly different locomotor ability from their corre-
sponding age-matched control counterparts throughout the pe-
riod tested (Fig. 4). Thus, the progressive loss of dopaminergic
neurons in R275Wmutant flies is associated with their declining
locomotor ability, as in the case observed with parkin null flies.
Parkin R275Wmutant flies are more susceptible to
rotenone-induced neurotoxicity
Next, we challenged the various transgenic flies with rotenone to
examine the relative susceptibility of their dopaminergic neurons
to degeneration in response to a PD-linked environmental neu-
rotoxin. We found that parkin null flies are especially susceptible
to rotenone-induced toxicity (data not shown) and have ex-
cluded them from this study. Consistentwith previously reported
effect of rotenone on dopaminergic neuronal survival in Dro-
sophila (Coulom and Birman, 2004), examination of TH-
positive, PPL1 dopaminergic neurons of flies treated with rote-
none for 15 d reveals a significant loss in all the fly brains,
although flies overexpressing wild-type human parkin appear to
be least affected among those examined (Fig. 5A). Morphologi-
cally, of the surviving PPL1 neurons examined, the ones in the
R275W fly brain seem to be the most compromised (Fig. 5A).
Quantitative analysis of the dopaminergic neuronal population
in these rotenone-treated flies reveals an accelerated loss of do-
paminergic neurons in all clusters compared with untreated flies
(compare Figs. 5B, 2B). However, when compared with treated
control flies, the PPL1 neurons in R275W transgenic flies are
modestly but significantly more susceptible to rotenone-induced
degeneration (Fig. 5B). Conversely, overexpression of normal






























Figure 1. Pan-neuronal expression of parkin mutants in transgenic Drosophila. A, Anti-
human parkin (hparkin) (green) and anti-elav (red) immunostaining of whole-mount adult
brains derived from 20-d-old transgenic flies expressing normal or mutant parkin species, as
indicated. B, Left, Anti-parkin immunoblot of detergent-soluble (S) and detergent-insoluble
(P) fractionated brain lysates derived from 20-d-old wild-type (WT) or transgenic (Tg) adult fly
brains. Right, As aboveexcept that three timesmorebrain lysates fromR275Wflieswere loaded
relative to those from wild-type parkin-expressing flies. Membranes were stripped and re-
probedwith anti-tubulin to reflect loading variations. Asterisks denotes nonspecific bands (ge-
notype: elav-GAL4/; UAS-hParkin/, control elav-GAL4/)
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three clusters (PPL1, PPL2, and PAM) of
dopaminergic neurons against rotenone-
mediated neurotoxicity (Fig. 5B) (data not
shown for PAM). This is consistent with
the known neuroprotective roles of parkin
(Cookson, 2003; Feany and Pallanck,
2003) and our recent finding demonstrat-
ing that overexpressed parkin could pro-
tect cells against rotenone-induced toxic-
ity in vitro (Wang et al., 2005b). The degree
of dopaminergic neuronal loss in these
flies correlates well with their respective
climbing ability, measured over a 15 d pe-
riod (Fig. 5C). Consistent with an acceler-
ated loss of dopaminergic neurons, the
rotenone-treated flies examined show a
correspondingly accelerated decline in
their locomotory function that progresses
with age (compare Figs. 5C, 4), with the
R275W mutant flies exhibiting the most
drastic climbing impairment relative to
control flies over time (Fig. 5C). The latter
aligns with the greater susceptibility of se-
lect clusters of dopaminergic neurons in
R275W flies to rotenone-induced dys-
function (Fig. 5A,B). Interestingly, the
protective effects of overexpressed wild-
type human parkin over PPL1, PPL2, and
PAM neurodegeneration in flies appar-
ently translates to better locomotor per-
formance, which is especially evident at
day 15 of the climbing assay (Fig. 5C). To-
gether, our results suggest that parkin
R275W-expressing flies aremore suscepti-
ble to rotenone-induced neurodegenera-
tion and concomitant impairment in
climbing ability, whereas overexpression
of human parkin in flies could signifi-
cantly mitigate these defects induced by
the neurotoxin.
Expression of parkin R275Wmutant in
parkin null flies does not accelerate the degeneration of
dopaminergic neurons
Given the opposing outcomes mediated by the overexpression of
wild-type human parkin and the R275W mutant in flies, we ex-
amined their respective effects on dopaminergic neuronal integ-
rity in parkin null background. We overexpressed wild-type or
R275W human parkin in homozygous Drosophila parkin null
mutant, and these flies are designated hparkin/ and R275W/,
respectively.When driven by theDdc-GAL4 driver, the reduction
of dopaminergic neurons in the PPL1 and PAM clusters in 20-d-
old R275W/ flies is comparable with that exhibited by the par-
kin null mutant alone (Fig. 6A,B) (data not shown for PAM).
Conversely, overexpression of normal human parkin in parkin
null flies significantly protects the PPL1 and PAM neurons from
degenerating (Fig. 6A,B) (data not shown for PAM).Not surpris-
ingly, the performance of R275W/ flies on the climbing assay is
significantly poorer when compared with hparkin/ flies (Fig.
6C). Intriguingly, R275W/ flies also present themselves as
poorer climbers when compared with age-matched R275W flies
(Fig. 6C). Taking into account that R275W and parkin null flies
exhibit comparable climbing ability (Fig. 4), the expression of
R275W parkin mutant against parkin null background thus ap-
pears to aggravate the locomotory deficit of the latter.We remain
curious by this observation, because the overexpression of
R275W parkin mutant does not appear to accelerate the degen-
eration of dopaminergic neurons in parkin null flies. However, it
is possible that R275W parkin mutant expression may affect the
function of surviving neurons.
Parkin R275Wmutant flies exhibit pleiomorphic
mitochondrial abnormalities
Because the loss of parkin in flies has consistently been shown to
result in muscle-associated mitochondrial pathology (Greene et
al., 2003; Pesah et al., 2004; I. E. Clark et al., 2006; Park et al., 2006;
Yang et al., 2006), we also generated transgenic flies expressing
the various parkin species under the direction of a muscle-
specific promoter (24B-GAL4) to examine their respective con-
tribution toward the maintenance of mitochondrial integrity.
Consistent with previous reports (Greene et al., 2003; Pesah et al.,
2004), we detected prominent mitochondrial defects in the indi-
rect flight muscles of parkin null flies (Fig. 7G,H). Although
muscle-specific expression of parkin R275W in flies did not pro-




















































Figure 2. Expression of parkin R275W mutant in flies promotes dopaminergic neuronal degeneration in select clusters. A,
Representative confocal microscopy images showing TH-positive (red) dopaminergic neurons in the PPL1 cluster of 20-d-old
control (CTRL) and parkin null flies (PK/) as well as in transgenic flies expressingwild-type (WT) ormutant parkin species, as
indicated. B, Bar graph showing the number of dopaminergic (DA) neurons in different clusters of the various fly species, as
depicted by different shades shown in the figure (*p 0.05, **p 0.01, Student’s t test; n 10). C, Representative confocal
microscopy images showing TH-positive (red) dopaminergic neurons in the PAM cluster of 20-d-old control and parkin null flies
(PK/) as well as in transgenic flies expressing normal or mutant parkin species, as indicated. PAM cluster in top row (boxed)
are shown at highermagnification in corresponding bottom row (genotype: Ddc-Gal4/; UAS-hParkin/, control Ddc-Gal4/)
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indirect flightmuscles are nonetheless typified by a significant num-
ber of abnormal mitochondrion (Fig. 7C,D). Notably, parkin
R275W flies exhibit markedly pleiomorphic mitochondrial pathol-
ogies (supplemental Fig. S1, available at www.jneurosci.org as
supplemental material). Although a large number of these or-
ganelles contain enlarged vacuolar structures surrounded by lay-
ers of concentric membranous structures (Fig. 7D) (supplemen-
tal Fig. S1, available at www.jneurosci.org as supplemental
material), some have disorganized cristae, whereas others have
degeneratedmembranes (supplemental Fig. S1, available atwww.
jneurosci.org as supplemental material). Conversely, none of
these abnormal mitochondrial structures are prevalent in the in-
direct flight muscles of 24B-GAL4-driven transgenic flies ex-
pressing wild-type (Fig. 7A,B) or G328Emutant (Fig. 7E,F) par-
kin. In these flies, the mitochondria in the indirect flight muscles
are generally intact (Fig. 7A,B,E,F). Although not exactly reca-
pitulating the defectivemitochondrial phenotype of theDrosoph-
ila parkin null mutant, it is interesting to note that muscle-
specific expression of parkin R275W in flies similarly produces
marked mitochondrial abnormalities. We also examined the mi-
tochondrial morphology of hparkin/ and R275W/ flies with
the transgene expression driven by 24B-GAL4 driver. Consistent
with our previous observation that overexpression of wild-type
human parkin in parkin null flies affords marked protection
against dopaminergic neuronal degeneration (Fig. 6A,B), we ob-








Figure 3. Selective dopaminergic neuronal loss in R275Wmutant flies.A,B, Representative
confocalmicroscopy images showing TH-positive (red) dopaminergic neurons in the PPL1 clus-
ter (A) and 5-HT-positive neurons (red) of 20-d-old transgenic flies expressing wild-type (WT)
































Figure 4. Parkin null and transgenic parkin R275W flies exhibit impaired climbing ability.
Bar graph showing thepercentage of flies at different days after eclosion that reached the topof
assay column after 1 min. The various fly strains examined are depicted by different shades
shown in the figure (*p 0.05, **p 0.01, Student’s t test; n 20) (genotype:Ddc-Gal4/;





























































Figure 5. Exposure to rotenone accelerates PPL1 dopaminergic neurodegeneration and lo-
comotor deficits in transgenic parkin R275W mutant flies. A, Representative confocal micros-
copy images showing TH-positive (red) dopaminergic neurons in the PPL1 cluster of 15-d-old,
rotenone-treated, transgenic flies expressing wild-type (WT) or mutant parkin species, as indi-
cated. B, Bar graph showing the number of dopaminergic (DA) neurons in different clusters of
the various fly species treated with rotenone, as depicted by different shades shown in the
figure (*p 0.05, **p 0.01, Student’s t test; n 10). C, Bar graph showing the climbing
scores of the various rotenone-treated flies at different days after eclosion, as depicted by
different shades shown in the figure (*p 0.05, **p 0.01 Student’s t test; n 20) (geno-
type: Ddc-Gal4/; UAS-hParkin/, control Ddc-Gal4/).
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parkin null flies in the presence of wild-type human parkin ex-
pression (Fig. 7I–L). Conversely, the abnormal mitochondrial
morphology associated with parkin null flies persists in the pres-
ence of R275Wmutant expression (Fig. 7M,N). Thus, wild-type
human parkin, but not R275Wmutant, appears to have the abil-
ity to rescue the mitochondrial phenotype of parkin null flies.
Discussion
The major finding of our study is that parkin R275W mutant
expression in vivo could exert neurotoxic effects in the presence
of the wild-type protein. When expressed as a transgene in Dro-
sophila, parkinR275Wmutant triggers the degenerationof dopami-
nergic neurons in select clusters and concomitantly results in loco-
motordeficits.Furthermore, flies expressing theR275Wmutantalso
promote mitochondrial abnormalities and appear more suscep-
tible to rotenone-induced neurotoxicity. Together, our results
suggest that heterozygous expression of select parkin mutations
in vivo may mediate pathogenic outcomes and confer increased
susceptibility of dopaminergic neurons to degeneration.
Although parkin-linked disease transmission is presumed to
occur in a recessive manner, the expanding number of reports
associating single parkin mutation with increased risk for PD has
raised questions on the mode of disease transmission by parkin
mutations (Klein et al., 2007). To date, several parkin mutations
occurring on different regions of the protein have been found in
heterozygous carriers (supplemental Table S1, available at www.
jneurosci.org as supplemental material). Interestingly, heterozy-
gous PD cases harboring the R275W mutation are a recurrent
theme in these studies (supplemental Table S1, available at www.
jneurosci.org as supplementalmaterial). However, the identifica-
tion of heterozygous parkinmutations remains controversial. In-
deed, A. West et al. (2002) demonstrated that single parkin
mutation cases are often overestimated in the literature. Impor-
tantly, they also found in half of their samples examined that
single parkin mutations exist as bona fide heterozygous muta-
tions (A. West et al., 2002; West and Maidment, 2004). Another
concern over heterozygous parkin mutation carriers is that they
may occur incidentally. However, at least two recent case control
studies of the parkin gene in early- and late-onset PD reveal the
presence of several heterozygous parkin mutations, including
R275W, that are not found in control individuals, thereby pro-
viding a direct association between heterozygous parkin muta-
tions and increased susceptibility for PD (Oliveira et al., 2003;
L. N. Clark et al., 2006). Notwithstanding the controversy sur-
rounding the existence of single parkin mutations, whether and
how heterozygous parkin condition affects dopaminergic neuro-
nal survivability remains obscure.
The importance of functional parkin to dopaminergic neuro-
nal survival is probably related to the multitude of neuroprotec-
tive roles it serves (Cookson, 2003; Feany and Pallanck, 2003).
Supporting this, we found that flies overexpressing wild-type hu-
man parkin aremore resistant to rotenone-induced degeneration
and associated locomotor defects. Moreover, expression of wild-
type human parkin in parkin null flies effectively prevents select
dopaminergic neurons fromdegenerating. AlthoughDdc-GAL4-
driven hparkin/ flies recorded similarly poor climbing scores to
parkin null flies, this is likely attributable to the inability of Ddc-
GAL4-driven hparkin expression to compensate for the wide-
spreadmuscle pathology in parkin null flies as reported by others
(Greene et al., 2003; Pesah et al., 2004) and in this study. Notably,
when driven by 24B-GAL4, wild-type but not R275W human
parkin expression in parkin null flies significantly mitigates the
mitochondrial phenotype of the latter. This is consistent with
previous reports by others showing that expression of wild-type
Drosophila parkin using 24B-GAL4 could rescue dparkin null
phenotype (Greene et al., 2003; Pesah et al., 2004). The apparent
protection afforded by wild-type human parkin against dopami-
nergic neurodegeneration and mitochondrial pathology in par-
kin null flies suggests a certain degree of functional conservation
between human and fly parkin.
Given its broad-spectrum neuroprotective roles, one could
envisage that parkin haploinsufficiency could increase the risk of
heterozygous parkin mutation carriers for PD. Consistent with
this, we and others have demonstrated previously that age, mu-
tations, and PD-linked stress could deplete the availability of sol-
uble functional parkin in the brain (LaVoie et al., 2005; Sriram et
al., 2005; Wang et al., 2005a,b; Wong et al., 2007) and, as such,
may underlie the progressive susceptibility of the brain to degen-
eration. Furthermore, a promoter variant of parkin associated
with a lower expression of parkin occurs more commonly in PD
cases than in controls (A. B. West et al., 2002). However, the

























































Figure 6. Overexpression of wild-type and R275W parkin in parkin null flies exert different
effects on dopaminergic neuronal survivability. A, Bar graph showing the number of dopami-
nergic (DA) neurons in different clusters of 20-d-old hparkin/ and R275W/ flies, as de-
pictedbydifferent shades shown in the figure. Data for control andparkinnull flieswerederived
from Figure 2 (*p 0.05, **p 0.01, Student’s t test; n 10). B, Representative confocal
microscopy images showing TH-positive (red) dopaminergic neurons in the PPL1 cluster of
20-d-old old hparkin/ and R275W/ flies, as indicated. C, Bar graph showing the climbing
scores of the various mutant flies, as indicated, at 20 d after eclosion (*p 0.05, **p 0.01,
Student’s t test; n 20) (genotype:UAS-hParkin, park1/park1, Ddc-Gal4, control Ddc-Gal4/).
8568 • J. Neurosci., August 8, 2007 • 27(32):8563–8570 Wang et al. • Parkin R275WMutant Causes DA Neurodegeneration
a proportion of single parkin mutation-linked PD cases cannot
be excluded. In particular, a recent family-based study conducted
in Germany implicates the transmission of the R275Wmutation
as an autosomal dominant trait, thereby providing additional
support for the notion that single R275Wparkinmutationmight
be sufficient to cause disease (R. Krueger, personal communica-
tion). Supporting this, our current study demonstrates that the
overexpression of parkin R275W in Drosophila is toxic to dopa-
minergic neuronal survival, albeit in select clusters. Furthermore,
R275W expression in Drosophila flight muscles also promotes
mitochondrial abnormalities. Thus, heterozygous parkin R275W
expression in vivo may contribute to pathogenecity. Interestingly,
our observations corroborate with a very recent study conducted by
Sang et al. (2007) who showed that expression of parkin T240R and
Q311X mutants in Drosophila causes age-dependent, selective de-
generation of DA neurons accompanied by progressive motor im-
pairment. The dissimilar outcomesmediated byR275WandG328E
mutants in flies may be related to their different properties, as ob-
served in our previous in vitro study (Wang et al., 2005a).
In our current study, we adopted an unbiased confocal
microscopy-based quantitative method described recently by
Whitworth et al. (2005) to detect subtle neuronal loss in the fly
brains. Similar to the observationmade by
Whitworth et al. with parkin null mutants,
we detect comparable loss in the number
of dopaminergic neurons within the PPL1
cluster in our parkin null flies at 20 d after
eclosion. Furthermore, we also observe an
obvious loss of dopaminergic neurons in
the PAMcluster of these flies. Importantly,
R275W parkin-overexpressing flies show
the same degeneration pattern as parkin
null flies, and both thesemutant fly species
exhibit marked mitochondrial pathology,
suggesting that heterozygous parkin mu-
tations could result in similar outcomes to
that arising from the overt loss of parkin
function. It is noteworthy that flies ex-
pressing the R275Wmutant also appear to
be more susceptible to rotenone-induced
neurotoxicity. Although accelerated neu-
ronal loss is observed in all the dopaminer-
gic clusters in the various fly strains after
rotenone treatment, the PPL1 neurons in
R275W are significantly more affected. In-
terestingly, the selective impact on neuro-
nal integrity exerted by the expression of
R275W in flies correlates well with their
impaired climbing ability compared with
age-matched control flies. Although previ-
ous studies have attributed compromised
locomotory activity observed in parkin
null flies primarily to defects in their mus-
culature (Greene et al., 2003; Pesah et al.,
2004), our results with Ddc-driven parkin
R275W flies show that dopaminergic neu-
rodegeneration in select clusters alone is
sufficient to trigger climbing defects. Fur-
thermore, the protection of similar clusters
of neurons by the Ddc-driven expression of
wild-type human parkin translates to better
climbing scores. It is thus tempting to sug-
gest a direct association between dopami-
nergic neurodegeneration and locomotory dysfunction in flies, a
phenomenon that is seen in PD patients.
How the expression of R275Wmutant influences the function
of endogenous parkin remains to be elucidated, but its expression
does not appear to aggravate the dopaminergic neurodegenera-
tion process when expressed in parkin null flies. Although the
latter is consistent with the R275W mutant parkin acting as a
dominant-negative protein, we remain intrigued by the poorer
climbing scores of R275W/ flies compared with R275W and
parkin null flies. Furthermore, the abnormal mitochondrial phe-
notype observed in the flight muscles of R275W mutant flies is
qualitatively different from that seen in parkin null flies, suggest-
ing that R275W parkin mutant may exert toxic effects in vivo via
a different mechanism from that produced by the overt loss of
parkin expression. As with all experiments involving the expres-
sion of transgenes in a heterologous system, we cannot com-
pletely exclude the possibility that the phenotypic characteristics
exhibited by R275W mutant flies arise from neomorphic mani-
festations associated with the expression of a foreign gene. How-
ever, several observations made in this study would argue against
R275W mutant acting as a neomorph. First, Ddc-driven expres-
sion of R275W mutant in flies affects the same clusters of dopa-

















Figure 7. Mitochondrial defects in parkin R275Wmutant flies. TEM analysis of indirect flightmuscles of 20-d-old flies express-
ing wild-type human parkin (WT) (A,B), R275W (C,D), G328E (E, F ), or lacking endogenous parkin (PK/) (G,H ) (genotype:
24B-Gal4/; UAS-hParkin/). The same analysis is performed in 2-d-old parkin null flies (I, J ) or those expressing wild-type
humanparkin (K, L) or R275W(M,N ) against parkinnull background (genotype:UAS-hParkin, park1/park1, 24B-Gal4 ). Scale bars:
A, C, E, G, I, K,M, 1M; B, D, F, H, J, L, N, 0.5M.
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minergic neurons as those in parkin null flies. Second, although
the effects mediated by R275W and parkin null mutant on Dro-
sophila flight muscle are not exactly identical, they nonetheless
promote a similar outcome, i.e., mitochondrial abnormalities.
Third, compared with the R275W mutant, the better-expressed
parkin G328E mutant behaves as a relatively benign foreign pro-
tein in Drosophila. Importantly, when we crossed wild-type
parkin-expressing flies with R275W mutant flies, we found that
their coexpression significantly mitigates the loss of PPL1 dopa-
minergic neurons observed inR275W flies (supplemental Fig. S2,
available at www.jneurosci.org as supplemental material). Al-
though the exact mechanism of R275Wmutant-mediated toxic-
ity remains to be clarified, it is apparent that the R275W flymodel
recapitulates the essential symptomatic features of PD and thus
represents an ideal in vivomodel of parkin dysfunction.Given the
demonstrated pathogenicity of R275Wmutant parkin expression
in flies, our results may also help explain the increased suscepti-
bility of heterozygous parkin carriers to develop PD.
In summary, our study provided important in vivo evidence
demonstrating that select parkin mutations could generate
markedneurotoxicity in vivo.Whether the neurotoxic effectsme-
diated by thesemutants could indeed account for a proportion of
single parkin mutation-linked PD cases remains to be estab-
lished. Additional study should help elucidate the pathogenic
mechanism caused by these mutations.
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